MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
4.000
+0.010
+0.25%
After Hours: 4.000 0 0.00% 16:10 02/13 EST
OPEN
4.000
PREV CLOSE
3.990
HIGH
4.140
LOW
3.890
VOLUME
39.96K
TURNOVER
--
52 WEEK HIGH
7.36
52 WEEK LOW
1.470
MARKET CAP
98.18M
P/E (TTM)
-1.2324
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARTV last week (0202-0206)?
Weekly Report · 4d ago
Weekly Report: what happened at ARTV last week (0126-0130)?
Weekly Report · 02/02 09:16
Weekly Report: what happened at ARTV last week (0119-0123)?
Weekly Report · 01/26 09:16
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)
TipRanks · 01/21 16:40
Artiva Biotherapeutics To Highlight Cost-Effectiveness Of AlloNK In Community Rheumatology Practice And Continued Durability Of AlloNK In Non-Hodgkin Lymphoma At 2026 Tandem Meetings
Benzinga · 01/21 13:04
Artiva Biotherapeutics to Present Data on AlloNK Cost-Effectiveness and Durability at Tandem Meetings
Reuters · 01/21 13:01
Artiva Biotherapeutics Highlights AlloNK Cost-Effectiveness and Durability in New Clinical Trial Data
Reuters · 01/21 13:00
Weekly Report: what happened at ARTV last week (0112-0116)?
Weekly Report · 01/19 09:18
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.